Clinical Aspects of the Protective Effects of Prostaglandins on Non-Steroidal Anti-Inflammatory Drug-Associated Mucosal Injury

  • D. Y. Graham
Conference paper

Abstract

Major clinical problems that occur in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) include dyspepsia, gastric (and possibly duodenal) ulcer, gastrointestinal bleeding, and gastric or duodenal perforation. Another problem is that many physicians feel compelled to treat visible mucosal damage associated with the administration of aspirin or other NSAIDs. The pathogenesis of NSAID-induced mucosal damage is still unclear; important variables include NSAID dosage, dosing interval, route of administration, formulation, and the solubility of the compound in the acid milieu of the stomach.

Keywords

Placebo Sulfide Aspirin Osteoarthritis Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lanza FL (1984) Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other non-steroidal anti-inflammatory agents. Am J Med 77 (suppl 1A): 19–24PubMedGoogle Scholar
  2. 2.
    Graham DY, Smith JL, Holmes GI, Davies RO (1985) Non-steroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa, Clin Pharmacol Ther 38: 65–70PubMedCrossRefGoogle Scholar
  3. 3.
    Osnes M, Larsen S, Eidsaunet W, Thom E (1979) Effect of diclofenac and naproxen on gastroduodenal mucosa. Clin Pharmacol Ther 26: 399–405PubMedGoogle Scholar
  4. 4.
    Tronstad RI, Aadland E, Holler T, Olaussen B (1985) Gastroscopic findings after Treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol 20: 239–242.CrossRefGoogle Scholar
  5. 5.
    Hradsky M (1981) Endoscopic Evaluation of gastric tolerance to fenclofenac. Upsala J Med Sci 86: 99–103PubMedCrossRefGoogle Scholar
  6. 6.
    Halvorsen L, Dotevall G, Sevelius H (1973) Comparative effects of aspirin and naproxen on gastric mucosa. Scan J Rheumatol 2: 43–7CrossRefGoogle Scholar
  7. 7.
    Lehtola J, Sipponen P (1977) A gastroscopic and histologic doubleblind study of the effects of diclofenac and naproxen on the human gastric mucosa. Scand J Rheumatol 6: 97–102PubMedCrossRefGoogle Scholar
  8. 8.
    Graham DY, Smith JL (1986) Aspirin and the stomach. Ann Intern Med 104: 390–8PubMedGoogle Scholar
  9. 9.
    Larkai EN, Smith JL, Lidsky MD, Graham DY (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153–1158PubMedGoogle Scholar
  10. 10.
    Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C et al (1979) Incidence of gastric lesions in patients with rheumatoid disease on chronic aspirin therapy. Ann Intern Med 91: 517–20PubMedGoogle Scholar
  11. 11.
    Bianchi Porro G, Lazzaroni M, Petrillo M (1982) Gastroscopy in elderly patients. Curr Med Res Opin 7 (Suppl 1): 96–103Google Scholar
  12. 12.
    Lockard OO, Ivey KJ, Butt JH, Silvoso GR, Sisk C, Holt S (1980) The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endoscopy 26: 5–7CrossRefGoogle Scholar
  13. 13.
    Morris AD, Holt SD, Silvoso GR, Hewitt J, Tatum W, Grandione J, et al (1981) Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment.Scan J Gastroent 16 (Suppl 67): 131–5Google Scholar
  14. 14.
    Caruso I, Bianchi Porro G (1980) Gastroscopic evaluation of anti-inflammatory agents. Br Med J 280: 75–8PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper SA (1983) New peripherally-acting oral analgesic agents. Ann Rev Pharmacol Toxicol 23: 617–47CrossRefGoogle Scholar
  16. 16.
    Brogden RN, Heel RC, Speight TM, Avery GS (1981) Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 22: 165–87PubMedCrossRefGoogle Scholar
  17. 17.
    Luftschein S, Bienenstock H, Varady JC, Stitt FW (1979) Increasing dose of naproxen in rheumatoid arthritis: Use with and without corticosteroids. J Rheumatol 6: 397–404Google Scholar
  18. 18.
    Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, Paulus HE (1982) Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther 31: 733–40PubMedCrossRefGoogle Scholar
  19. 19.
    Berry H, Nichols A (1985) An open study of 1.5 g naproxen daily in osteoarthritis. Curr Med Res Opin 9: 366 - 70PubMedCrossRefGoogle Scholar
  20. 20.
    Ekstrand R, Alvan G, L’e Orme M, Lewander R, Palmer L, Sarby B (1980) Double-blind doseresponse study of indomethacin in rheumatoid arthritis. Eur J Clin Pharmacol 17: 437–42PubMedCrossRefGoogle Scholar
  21. 21.
    Baragar FD, Smith TC (1987) Drug interaction studies with sodium meclofenamate (meclomen®). Curr Ther Res 23: S51–9Google Scholar
  22. 22.
    Gibberd FB (1966) Dyspepsia in patients with rheumatoid arthritis. Acta Rheum Scand 12: 112 - 21PubMedGoogle Scholar
  23. 23.
    Schiller KFR, Truelove SC, Williams DG (1970) Hematemesis and melaena, with special reference to factors influencing the outcome. Br Med J 2: 7–14PubMedCrossRefGoogle Scholar
  24. 24.
    Uddin J, Kraus AS, Kelly HG (1970) Survivorship and death in rheumatoid arthritis. Arth Rheum 13: 125–30CrossRefGoogle Scholar
  25. 25.
    Mutru O, Koota K, Isomaki H (1976) Causes of death in autopsied RA patients. Scand J Rheumatology 5: 239–40CrossRefGoogle Scholar
  26. 26.
    Monson RR, Hall AP (1979) Mortality among arthritics. J Chron Dis 29: 459–67CrossRefGoogle Scholar
  27. 27.
    Rasker JJ, Cosh JA (1981) Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 40: 115–20PubMedCrossRefGoogle Scholar
  28. 28.
    Morris AD, Holt SD, Silvoso GR, Hewitt J, Tatum W, Grandione J, Butt JH, Ivey KJ (1981) Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment. Scand J Gastroenterol 16: 131–5Google Scholar
  29. 29.
    Abruzzo JL (1982) Rheumatoid arthritis and mortality. Arth Rheum 25: 1020–3CrossRefGoogle Scholar
  30. 30.
    VanDenbrouche JP, Hazevoet HM, Cats A (1984) Survival and cause of death in gherumtroid arthritis: a 25-year prospective follow-up. J Rheumatol 11: 158–61Google Scholar
  31. 31.
    Mutru O, Laakso M, Isomaki H, Koota K (1985) Ten-year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 290: 1811–13CrossRefGoogle Scholar
  32. 32.
    Mitchell DM, Spritz PW, Young DY, Bloch DA, McShane DJ, Fries JF (1986) Survival, prognosis and causes of death in rheumatoid arthritis. Arth Rheum 29: 706–14CrossRefGoogle Scholar
  33. 33.
    Collier DSTJ, Pain JA (1985) Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 26: 359–63PubMedCrossRefGoogle Scholar
  34. 34.
    Alexander AM, Veitch GBA, Wood JB (1985) Anti-rheumatic and analgesic drug usage and acute gastrointestinal bleeding in elderly patients. J Clin Hosp Pharm 10: 89–93PubMedGoogle Scholar
  35. 35.
    Clinch D, Banergee AK, Ostick G, Levy DW (1983) Non-steroidal anti-inflammatory drugs and gastrointestinal adverse effects. J R Coll Physicians (London) 17: 228–30Google Scholar
  36. 36.
    Llewelyn JG, Pritchard MH (1983) Acute gastric haemorrhage and its relationship to the use of anti-inflammatory analgesics (NSAIDs). Ann Rheum Dis 42: 228–9Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • D. Y. Graham

There are no affiliations available

Personalised recommendations